Spots Global Cancer Trial Database for Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
Official Title: Phase II Clinical Study of Fruquintinib Combined TAS102 for Second-line Treatment of Advanced Gastric Cancer
Study ID: NCT06102785
Conditions
Interventions
Study Description
Brief Summary: This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib combined with TAS102 for second-line treatment of advanced gastric cancer.
Detailed Description: A prospective study of Fruquintinib combined with TAS-102 for the posterior line treatment of advanced colorectal cancer is ongoing (NCT05004831). Both Fuquinitinib and TAS-102 are oral drugs, which are convenient to use and avoid the burden of frequent hospitalization. Whether this combination has considerable efficacy in gastric cancer is not clear.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Contact Details
Name: Ting Deng, MD
Affiliation: Tianjin Medical University Cancer Institute and Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
